MX2011008289A - Tabletas para terapia combinada. - Google Patents

Tabletas para terapia combinada.

Info

Publication number
MX2011008289A
MX2011008289A MX2011008289A MX2011008289A MX2011008289A MX 2011008289 A MX2011008289 A MX 2011008289A MX 2011008289 A MX2011008289 A MX 2011008289A MX 2011008289 A MX2011008289 A MX 2011008289A MX 2011008289 A MX2011008289 A MX 2011008289A
Authority
MX
Mexico
Prior art keywords
tablets
formula
combination therapy
compound
iii
Prior art date
Application number
MX2011008289A
Other languages
English (en)
Inventor
Mark M Menning
Reza Oliyai
Joanna M Koziara
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41722740&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011008289(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MX2011008289A publication Critical patent/MX2011008289A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención proporciona formas de dosis sólidas (por ejemplo, tabletas) que comprenden un compuesto de la Fórmula I, un compuesto de la Fórmula II, un compuesto de la Fórmula III y una sal de la Fórmula IV. [inserto Fórmula I II, III, IV].
MX2011008289A 2009-02-06 2010-02-04 Tabletas para terapia combinada. MX2011008289A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15065509P 2009-02-06 2009-02-06
US15065209P 2009-02-06 2009-02-06
PCT/US2010/023226 WO2010091197A2 (en) 2009-02-06 2010-02-04 Tablets for combination therapy

Publications (1)

Publication Number Publication Date
MX2011008289A true MX2011008289A (es) 2011-09-15

Family

ID=41722740

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008289A MX2011008289A (es) 2009-02-06 2010-02-04 Tabletas para terapia combinada.

Country Status (31)

Country Link
US (2) US20100285122A1 (es)
EP (1) EP2393485B1 (es)
JP (2) JP5611242B2 (es)
KR (2) KR101645759B1 (es)
CN (1) CN102307573B (es)
AP (1) AP3250A (es)
AR (1) AR075369A1 (es)
AU (1) AU2010210598B2 (es)
BR (1) BRPI1008664A2 (es)
CA (1) CA2750521A1 (es)
CL (1) CL2011001885A1 (es)
CY (1) CY1116852T1 (es)
DK (1) DK2393485T3 (es)
EA (2) EA030123B1 (es)
EC (1) ECSP11011307A (es)
ES (1) ES2548886T3 (es)
HK (1) HK1164737A1 (es)
HR (1) HRP20151009T1 (es)
HU (1) HUE025822T2 (es)
IL (1) IL214227A (es)
MX (1) MX2011008289A (es)
NZ (1) NZ594214A (es)
PE (1) PE20110994A1 (es)
PL (1) PL2393485T3 (es)
PT (1) PT2393485E (es)
SG (3) SG173544A1 (es)
SI (1) SI2393485T1 (es)
SM (1) SMT201500266B (es)
TW (1) TWI444367B (es)
UY (1) UY32424A (es)
WO (1) WO2010091197A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA020489B1 (ru) 2006-07-07 2014-11-28 Джилид Сайэнс, Инк. Модуляторы фармакокинетических свойств лекарственных средств
SG183059A1 (en) * 2007-02-23 2012-08-30 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
PL2296633T3 (pl) 2008-05-02 2016-03-31 Gilead Sciences Inc Zastosowanie cząsteczek stałych nośników dla udoskonalenia przetwarzalności środka farmaceutycznego
TWI556840B (zh) 2010-11-19 2016-11-11 吉李德科學股份有限公司 治療用組成物
WO2012072580A1 (en) * 2010-11-29 2012-06-07 Formac Pharmaceuticals N.V. Compressed formulations of ordered mesoporous silicas
SI2729130T1 (en) * 2011-07-07 2018-03-30 Janssen Sciences Ireland Uc Combined formulations of darunavir
RS55353B2 (sr) 2011-08-16 2023-11-30 Gilead Sciences Inc Tenofovir alafenamid hemifumarat
WO2013115916A1 (en) * 2012-02-03 2013-08-08 Gilead Sciences, Inc. Combination therapy comprising gs-7340 and cobicistat for use in the treatment of viral infections
EA026138B1 (ru) * 2012-02-03 2017-03-31 Джилид Сайэнс, Инк. Комбинированная терапия, включающая тенофовир алафенамида гемифумарат и кобицистат, для применения для лечения вирусных инфекций
US20150045366A1 (en) * 2012-03-01 2015-02-12 Gilead Sciences, Inc. Spray dried formulations
CN103830192A (zh) * 2012-11-27 2014-06-04 安徽贝克生物制药有限公司 一种可粉末直接压片的富马酸替诺福韦二吡呋酯片剂及制备方法
DK3067358T3 (da) 2012-12-21 2019-11-04 Gilead Sciences Inc Polycykliske carbamoylpyridon-forbindelser og deres farmaceutiske anvendelse
PT3607939T (pt) 2015-06-30 2022-09-12 Gilead Sciences Inc Formulações farmacêuticas compreendendo tenofovir e emtricitabina
CN113546052A (zh) 2015-11-09 2021-10-26 吉利德科学公司 治疗人免疫缺陷病毒的治疗组合物
ES2806604T3 (es) 2016-02-02 2021-02-18 Sandoz Ag Formas cristalinas de monofumarato de tenofovir alafenamida

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA923640B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
DE10153078A1 (de) * 2001-10-30 2003-05-22 Degussa Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen
CN100375742C (zh) * 2002-11-20 2008-03-19 日本烟草产业株式会社 4-氧代喹啉化合物及其用途
SK2662004A3 (sk) 2002-11-20 2005-06-02 Japan Tobacco, Inc. Zlúčenina s obsahom 4-oxochinolínu a jej použitie ako inhibítora integráz
JP3567162B1 (ja) * 2002-11-20 2004-09-22 日本たばこ産業株式会社 ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
DE602004014470D1 (de) 2003-01-14 2008-07-31 Gilead Sciences Inc Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
MY134672A (en) 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
KR20080091767A (ko) * 2005-12-14 2008-10-14 씨아이피엘에이 엘티디. (테노포비어 및 라미뷰딘과 같은) 뉴클레오티드 역전사효소억제제 및 뉴클레오시드 역전사효소 억제제를 투여 단위의상이한 부분에 포함하는 약제학적 조합물
EA020489B1 (ru) * 2006-07-07 2014-11-28 Джилид Сайэнс, Инк. Модуляторы фармакокинетических свойств лекарственных средств
SG183059A1 (en) * 2007-02-23 2012-08-30 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics

Also Published As

Publication number Publication date
DK2393485T3 (en) 2015-10-26
CY1116852T1 (el) 2017-04-05
SMT201500266B (it) 2016-01-08
US20100285122A1 (en) 2010-11-11
AP3250A (en) 2015-05-31
JP2012517432A (ja) 2012-08-02
CL2011001885A1 (es) 2012-05-25
EA030123B1 (ru) 2018-06-29
KR20160093100A (ko) 2016-08-05
EA201190125A1 (ru) 2012-01-30
JP5911927B2 (ja) 2016-04-27
NZ594214A (en) 2013-05-31
US20150150810A1 (en) 2015-06-04
HUE025822T2 (en) 2016-04-28
SI2393485T1 (sl) 2015-10-30
EP2393485B1 (en) 2015-07-29
WO2010091197A3 (en) 2011-06-03
HRP20151009T1 (hr) 2015-10-23
KR101738325B1 (ko) 2017-05-19
IL214227A0 (en) 2011-09-27
IL214227A (en) 2017-01-31
CN102307573A (zh) 2012-01-04
EA021313B1 (ru) 2015-05-29
CN102307573B (zh) 2013-09-11
ECSP11011307A (es) 2011-10-31
KR20110122729A (ko) 2011-11-10
AP2011005857A0 (en) 2011-10-31
JP2014221845A (ja) 2014-11-27
TW201040142A (en) 2010-11-16
AR075369A1 (es) 2011-03-30
SG10201706215UA (en) 2017-08-30
WO2010091197A2 (en) 2010-08-12
PT2393485E (pt) 2015-10-23
PL2393485T3 (pl) 2015-12-31
UY32424A (es) 2010-09-30
ES2548886T3 (es) 2015-10-21
SG173544A1 (en) 2011-09-29
EA201491658A1 (ru) 2015-05-29
HK1164737A1 (en) 2012-09-28
KR101645759B1 (ko) 2016-08-04
SG2014007744A (en) 2014-05-29
AU2010210598A1 (en) 2011-08-25
AU2010210598B2 (en) 2015-03-05
JP5611242B2 (ja) 2014-10-22
EP2393485A2 (en) 2011-12-14
TWI444367B (zh) 2014-07-11
PE20110994A1 (es) 2012-01-24
BRPI1008664A2 (pt) 2016-03-08
CA2750521A1 (en) 2010-08-12

Similar Documents

Publication Publication Date Title
MX2011008289A (es) Tabletas para terapia combinada.
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
MX351892B (es) Combinaciones de compuestos inhibidores de akt y abiraterona y metodos de uso.
TN2011000291A1 (en) Purine compounds
JO3148B1 (ar) مركب مثبط لإشارات مسار notch
MX2009011211A (es) Indoles sustituidos en la posicion 7 inhibidores de mci-1.
TN2012000248A1 (en) Novel spiropiperidine compounds
MY160456A (en) Benzodiazepine bromodomain inhibitor
HK1154002A1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
MX2012004780A (es) Inhibidores de akt.
MY187718A (en) Pharmaceutical formulations
MY160392A (en) Triptolide prodrugs
UA107476C2 (uk) Фармацевтична субстанція на основі мітохондріально адресованих антиоксидантів
NZ700356A (en) Pyrazole compounds as sglt1 inhibitors
MX2013011926A (es) Derivados de glicosido y usos de los mismos.
JO3145B1 (ar) مركبات مفيدة لتثبيط chk1
MX2010001303A (es) Compuestos terapeuticos.
JO2979B1 (en) Cyclopropyl compounds
MY162348A (en) Therapeutic agent for chronic pain
UA105675C2 (uk) Бензодіазепіновий інгібітор бромодомену
UA103224C2 (ru) Таблетки для комбинированной терапии
MX2013006185A (es) Compuestos de 6-(piridinilmetoxi) -pirrolopiridina 3-sustituidos.
UA110609C2 (uk) Сполуки для інгібування ферменту протеасоми
UA45737U (ru) ЦИКЛОПЕНТИЛИДЕН-ГИДРАЗИД α-ПИРИДИНКАРБОНОВОЙ КИСЛОТЫ, ВЫЯВЛЯЮЩИЙ ПротивотуберкулезнУЮ АКТИВНОСТЬ

Legal Events

Date Code Title Description
FG Grant or registration